Pd16-07 Predicting Toxicity-related Docetaxel Discontinuation and Survival in Metastatic Castration-resistant Prostate Cancer Using Open Phase 3 Trial Data
Year: 2020
Type: article
Abstract: RESULTS: Overall, 1577 patients were included.Median (IQR) BMI was 28 (25-31) kg/m2.With respect to death of any cause, BMI emerged as a protective factor both as a continuous variable (HR: 0.96; 95%CI: 0.94,0.99;p[0.015) and as a categorical variable (obesity: HR: 0.71, 95%CI: 0.53,0.96;p[0.027).The inverse effect BMI on CSM was confirmed both as a continuous (SHR: 0.94; p[0.002) and as a categorical variable (SHR: 0.65; p[0.018).No interaction was detected between the BMI categories and the docetaxel dose at any level of our analyses (all p>0.05)CONCLUSIONS: Obese patients with mCRPC depicted a better cancer specific and overall survival compared to overweight and normal weight patients.The protective effect of BMI was not related to the higher dose of chemotherapy
Source: The Journal of Urology
Authors: Alberto Martini*, Anish B Parikh, John P Sfakianos, Nicola Fossati, Giorgio Gandaglia, Simone Scuderi, Donato Cannoletta, Giuseppe Fallara, Elio Mazzone, Armando Stabile, Francesco Barletta, Daniele Robesti, Carlo Bravi, Alberto Briganti, Francesco Montorsi, William K. Oh, Matthew D. Galsky, Che-Kai Tsao
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W3018665264